Search clinical trials for: LUM/IVA

Total 3510 results

Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Hillel Yaffe Medical Center

Unknown

Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients

Polycystic Ovary Syndrome | Infertility | Obese

Israel
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Cystic Fibrosis

Netherlands
Guangxi Medical University

Completed

Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection (SP/GC-HCC)

Liver Cancer

China
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
CHA University

Recruiting

Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS

No Condition

Korea, Republic of
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
University of Colorado, Boulder

Completed

Understanding Mechanisms of Exercise Behavior Change

Physical Activity | Overweight and Obesity | Incentives

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

United States, Canada
University of Colorado, Boulder

Completed

Understanding Mechanisms of Health Behavior Change

Diet Modification | Overweight and Obesity | Incentives

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark
Jie Qiao

Unknown

IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS

PCOS

China
Lumicell, Inc.

Recruiting

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

Peritoneal Metastases

United States
Lumicell, Inc.

Terminated

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Prostate Cancer | Neoplasm, Residual

United States
Washington University School of Medicine
Case Western Reserve University; University of Health and Allied Sciences

Completed

Safety and Efficacy of IDA for Onchocerciasis (DOLF IDA/Oncho)

Onchocerciasis

Ghana
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Democritus University of Thrace

Unknown

Development of a Validated Chart for Intermediate Vision Assessment

Presbyopia | Astigmatism | Myopia | Hyperopia

Greece
Lumicell, Inc.

Withdrawn

Feasibility Study of LUM Imaging System for Pancreatic Cancer

Pancreatic Cancer

United States
Lumicell, Inc.

Suspended

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

Glioblastoma | Low Grade Glioma of Brain | Metastasis to Brain

United States
Lumicell, Inc.
National Cancer Institute (NCI)

Completed

Intraoperative Detection of Residual Cancer in Breast Cancer

Breast Cancer

United States
Lumicell, Inc.
National Cancer Institute (NCI)

Recruiting

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer

United States
Lumicell, Inc.
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber...

Completed

Feasibility Study of Intraoperative Imaging in Breast Cancer

Breast Cancer

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Lumos Pharma

Active, not recruiting

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (OraGrowtH212)

Growth Hormone Deficiency

Chile
Lumos Pharma

Enrolling by invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) (OraGrowtH211)

Growth Hormone Deficiency

United States, Australia
Lumicell, Inc.
National Cancer Institute (NCI); Massachusetts General Hospital

Terminated

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Breast Cancer | Neoadjuvant Therapy

United States
Lumos Pharma

Active, not recruiting

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (OraGrowtH213)

Growth Hormone Deficiency

United States, Poland
Lumicell, Inc.
National Cancer Institute (NCI)

Completed

Investigation of Novel Surgical Imaging for Tumor Excision (INSITE)

Breast Cancer

United States
Medical University of Vienna

Completed

Seraseal for Endoscopic Hemostasis

Gastrointestinal Hemorrhage

Germany, Austria
H. Lundbeck A/S

Completed

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Healthy

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
University of Florida
Inventiva Pharma

Completed

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease (NAFLD) | Type 2 Diabetes (T2DM)

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Peking University People's Hospital
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Completed

The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR

Proliferative Diabetic Retinopathy

China
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
Lawson Health Research Institute

Active, not recruiting

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Neuroendocrine Carcinoma

Canada
Massachusetts General Hospital

Recruiting

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

NAFLD | NASH - Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Spain, Australia, United Kingdom, Germany, Ireland
University Health Network, Toronto

Recruiting

Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs

Atypical Femur Fracture

Canada
Eli Lilly and Company

Recruiting

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain (CPMP)

Chronic Low-back Pain | Osteoarthritis, Knee | Diabetic Neuropathic Pain

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland

Search clinical trials for: LUM/IVA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations